Medacta stock rises as H1 earnings beat forecasts, FY25 outlook reaffirmed

Medacta Group SA shares advanced after the Swiss medical device maker reported first-half adjusted EBITDA of €98.8 million, exceeding consensus by 8%, and adjusted EBIT by 13%, with its adjusted EBITDA margin rising to 28.7%. The company also achieved positive free cash flow of €3.6 million, up from negative €18.3 million, despite ongoing growth investments. UBS analysts lauded the results as a "strong print," and Medacta reaffirmed its full-year 2025 outlook for 16-18% revenue growth and an adjusted EBITDA margin of approximately 28% in constant currencies, signaling continued operational strength.

Analysis

Medacta Group SA (MOVE) demonstrated robust operational performance in its first-half results, significantly outperforming market expectations. The company reported an adjusted EBITDA of €98.8 million, an 8% beat against the €91 million consensus, and an adjusted EBIT that was 13% above estimates. Profitability showed marked improvement, with the adjusted EBITDA margin expanding to 28.7% from 26.9% in the prior-year period, while gross margin held steady at 68.3% despite foreign exchange headwinds. A pivotal development was the turnaround in free cash flow to equity, which shifted from a negative €18.3 million to a positive €3.6 million, signaling enhanced capital efficiency even as the company continues to fund growth investments. Management's confidence is underscored by the reiteration of its full-year 2025 guidance for 16% to 18% revenue growth and an adjusted EBITDA margin of approximately 28% in constant currencies. While UBS analysts acknowledged the results as a "strong print," their "neutral" rating and CHF151 price target suggest the positive news may be largely priced in, a sentiment reinforced by their note that guidance had already been raised earlier in the year.

Key Decisions for Investors

• Investors should view the significant earnings beat and reaffirmed high-growth guidance as confirmation of strong operational execution, which could sustain the stock's positive trajectory.
• The UBS 'neutral' rating suggests that much of the positive outlook may already be priced into the stock, warranting a valuation-sensitive approach before initiating or adding to positions.
• Monitor free cash flow generation in upcoming quarters, as its sustainability is crucial for funding the company's ambitious growth agenda without deteriorating the balance sheet.
• For income-focused portfolios, the projected increase in the dividend per share from €0.72 in 2024 to €0.86 in 2025, backed by solid earnings growth forecasts, offers an attractive capital return profile.